FTC chief calls for a ban on generic pay-for-delay deals

Share this article:
In the wake of an FTC report that so-called “authorized generics” lower prices, commission chairman Jon Leibowitz says Congress should pass pending legislation to ban or restrict a related mechanism known as pay-for-delay arrangements in which a branded drug company pays potential generic competitors to stay out of the market.

In a speech to the Center for American Progress, Leibowitz said eliminating such agreements could save $35 billion in healthcare costs over 10 years.

“From my perspective, … the decision about whether to restrict pay-for-delay settlements should be simple,” Leibowitz declared. “On the one hand you have savings to American consumers of $35 billion or more over 10 years, about $12 billion of which would be savings to the federal government, and the prospect of helping to pay for healthcare reform as well as the ability to set a clear national standard to stop anti-competitive conduct. On the other hand, you have a permissive legal regime that allows competitors to make collusive deals on the backs of consumers.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?